John R Stuelpnagel, Director, on August 11, 2026, sold 20,000 shares in 10x Genomics (TXG) for $1,155,055. Following the Form 4 filing with the SEC, Stuelpnagel has control over a total of 348,436 Class A common shares of the company, with 348,436 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1770787/000161071726000358/xslF345X05/form4.xml